| 1 | Assessment of SARS-CoV2 genome sequence recovery from four lateral flow device |
|----------|---|
| 2 | products available in the UK. |
| 3 | |
| 4 | Kuiama Lewandowski, Matthew Stokes, Alexandra Alexandridou, Abigail Fenwick, Mia L. White, |
| 5 | Jack Crook, Karly-Rai Rogers-Broadway, Catherine Ryan, Deborah A. Williamson, Richard |
| 6 | Vipond, Steven T. Pullan. |
| 7 | Affiliation: UK Health Security Agency, Specialised Microbiology and Laboratories. |
| 8 | |
| 9 | Acknowledgements |
| 10 11 | Evaluation and Innovation team and the wider UKHSA Pathogen Genomics Sequencing Laboratory team for their help |
| 12 | and support. |
| 13 | The views expressed are those of the authors and not necessarily those of the funding bodies or the Department of |
| 14 | Health and Social Care. |
| 15 | |
| 16 | Abstract (word count: 175) |
| 17 | Lateral flow tests have played a key role in the response to the COVID-19 pandemic and are likely |
| 18 | to be a major component of diagnostic strategies to combat future outbreaks of infectious disease. |
| 19 | One challenge posed by widescale use of lateral flow tests in the community is the loss of |
| 20 | sequence information to track virus evolution and epidemiology. |
| 21 | |
| 22 | Beyond their primary diagnostic function, it has been demonstrated that recovery of viral RNA for |
| 23 | genome sequencing purposes is possible, from positive lateral flow devices (LFDs). |
| 24 | To assess the robustness and broader applicability of this process, we assessed SARS-CoV-2 |
| 25 | RNA recovery and sequencing from the four major LFDs in use in the UK. |
| 26 | |
| 27 | Testing both cultured virus and residual clinical nasal swab samples demonstrated that |
| 28 | sequencing from LFD eluates is possible, at clinically relevant titres, within a reasonable |
| 29 | processing time frame post-use, and gave sequences concordant with routine methods, but |
| 30 | results varied across the four devices used. |
| 31 | This highlights the requirement for refinement of existing LFDs or of second-generation LFD |
| 32 | design, where sequencing is an intended output from positive LFDs. |
| 33 | |
| 34 | |
| | |

36 Introduction

Genomic sequencing of SARS-CoV-2 has had a major role in the public health response to the COVID-19 pandemic, enabling mapping of viral transmission at global and local levels, informing infection control measures, and identifying and tracking the emergence of new variants (1).

Viral transport media from nasal/oral swabs have been the most widely utilised sample source for SARS-CoV-2 WGS pipelines. Typically, these have been residual material from diagnostic testing, taken forward for genome sequencing (most commonly via whole genome tiling ampliconbased methods) upon positivity (2). However, point-of-care lateral flow device (LFD) tests, including self-test kits are replacing PCR as diagnostics in many settings (3), meaning opportunities for genomic characterisation of circulating variants are increasingly limited.

47

Multiple studies have demonstrated the possibility of retrieving viral nucleic acid from positive 48 49 LFDs. Martin et al., 2022 described an approach for whole-genome sequencing of SARS-CoV-2 from positive LFDs and demonstrated the application of this technique to PanBio and InnoScreen 50 51 devices collected as part of clinical care. The same device brands were also used to demonstrate 52 detection and whole genome sequencing of non-SARS-CoV-2 respiratory viruses present on the 53 COVID-19 LFD (5). Macori et al., 2022 demonstrated SARS-Cov-2 sequencing was possible from 54 PanBio and Clinitest devices. Rector et al., 2022 demonstrated that genomic material of SARS-COV-2, influenza virus, adenovirus and rotavirus can also be retrieved from their corresponding 55 positive LFDs, tested across 9 different device brands (Roche, FlowFlex, Newgene, Coris, Alltest, 56 57 Boson, OrientGene, AMP and Nadal), showing stability for up to three months post-use storage at room temperature, but noting that there were significant differences in RNA yields obtained 58 59 from different device buffers, highlighting the requirement for individual device testing prior to 60 routine use in sequencing.

61

In this study we aim to perform an assessment of sequencing from the LFD, focussed on those
 LFD brands currently in use in the UK, with a focus on the feasibility of performing the analysis in
 real-world relevant processing time frame.

65

67 Methods

68 Lateral Flow Devices assessed

Four brands of SARS-COV-2 LFD widely used in the UK were procured for assessment for
 recovery of SARS-COV-2 genomic material :

- FlowFlex COVID-19 Antigen Rapid Test (FlowFlex)
- COVID-19 SureScreen Lateral Flow Self-Test (SureScreen)
 - OrientGene Rapid Covid-19 (Antigen) Self-Test (OrientGene)
 - INNOVA SARS-CoV-2 Rapid Antigen Test (Innova)
- 74 75

73

76 Inactivated SARS-COV-2

77 Cell-cultured and X-ray-irradiation-inactivated SARS-COV-2 virions were provided by Virology

and Pathogenesis group, UKHSA Porton Down. A dilution series of samples was produced ranging from 10^5 to 10^1 PFU/ml (RT-gPCR C_t vales of 18, 25, 28, 32 and 35).

80

81 Clinical samples

- 82 Anonymous residual VTM from nasal swab samples was provided from routine UKHSA SAR-
- 83 COV-2 surveillance sequencing.
- 84

85 LFD loading

Mock or clinical samples were diluted 1:1 v/v with the corresponding LFD sample loading buffer and 70 μ I applied to the device via pipette. After 15 min the LFD result was read. Ambient incubation was continued for 45 min before elution.

89

90 Addition of preservatives

91 Where stated, 70 μ l of the tested preservative were added to the device via the sample loading 92 port once the result had been read. Viral sample titre for all preservative testing 10³ PFU/ml (RT-93 qPCR C_t 25).

- 94
- 95

96 LFD Elution

97 Strip removal method

The LFD was opened manually along the join line of the outer casing, the internal strip was removed using two pairs of tweezers, placed into a 2 ml tube containing 700µl of MagMAX

100 Viral/Pathogen Binding Solution (extraction buffer) and incubated for 60 min prior to nucleic acid101 extraction.

102

103 Centrifugation method

104 700 µl of extraction buffer was added to the LFD via the sample loading port. The device was
placed inside a 50 ml falcon tube, laid flat (face up) and incubated for 60 min. The tube containing
the LFD was centrifuged at 2000 rpm for 2 min to elute the extraction buffer from the device into
the falcon tube prior to nucleic acid extraction.

108

109 Nucleic Acid extraction

110 Samples were extracted via the KingFisher Flex platform using the MagMAX Viral/Pathogen

111 Nucleic Acid Isolation kits and 700µl of sample input, as per manufacturer's instructions.

112

113 SARS-COV-2 Sequencing and lineage calling

114 Samples were processed by the UKHSA Pathogen Genomics SARS-Cov-2 Sequencing Service,

- utilising the ARTIC network tiling amplicon scheme protocol (8), with primer scheme version 5.3.2.
- 116 (SARS-CoV-2 version 5.3.2 scheme release Laboratory ARTIC Real-time Genomic
- 117 Surveillance) and sequenced on an Oxford Nanopore GridION X5. Data analysis was performed
- by following the ARTIC network nanopore protocol for nCoV2019 (10) and lineage determined via
- 119 Pangolin (11).
- 120

121 RT-qPCR

122 RT-qPCR was performed using New England Biolabs, Luna SARS-CoV-2 RT-qPCR Multiplex

- Assay Kit. Assays were performed as per manufacturer's instructions for the multiplex detection
- of 2019-nCoV_N1 and 2019-nCoV_N2 targets. Reported C_t values are for the N1 target.
- 125
- 126

127 Results/Discussion

128

129 Preliminary testing of recovery utilising inactivated SARS-COV-2

- 130 A titration range of inactivated SARS-COV-2 virions was used to assess the four device brands,
- 131 with genomic material recovered by removal of the test strip (see methods).
- 132 We observed recovery of sufficient sequence information for lineage assignment (Typically > 70%
- 133 of total genome) at both 10^5 and 10^3 PFU/ml concentrations (Equivalent to a sample C_t of 18 and
- 134 25 respectively) from three of the four devices tested (Figure 1). SureScreen being the exception,
- 135 with reduced genome recovery across all concentrations tested. Samples with a concentration of
- 136 10^2 and above consistently produced a positive LFD on all brands tested.
- 137



139 Figure 1. Percentage of total genome sequence recovered following elution of SARS-COV-

- 140 2 virions from four brands of LFDs. Red line indicates 70% genome recovery (approximation
- 141 of level required for lineage determination).
- 142

143 Clinical sample testing

144 To assess recoverability from a clinically relevant sample type, we tested 40 residual nasal swab

- 145 VTM samples (used in COVID-19 surveillance sequencing). Residual material from each sample
- 146 was loaded upon each of the four LFD types for direct comparison.
- 147 Results again varied across devices. From OrientGene and Innova devices 80% of samples
- 148 achieved sufficient coverage for variant calling, whereas for FlowFlex and SureScreen devices
- only 25 and 20% of samples produced sufficient genome coverage respectively (Figure 2).
- 150 In all cases where a lineage call was achieved, they were concordant with the expected result
- 151 from initial sample sequencing.





Figure 2. Percentage of total genome sequence recovered following elution of clinical
 samples across each of the four devices. Red line indicates 70% genome recovery.

156

157 Elution efficiency and genome recovery

- To assess efficiency of elution of viral nucleic acid from the LFDs, and the effect upon sequence
 recovery, RT-qPCR was performed on a subset of the clinical samples and corresponding LFD
 eluates. A similar level of reduction in viral concentration was seen between the primary sample
 and the LFD eluate for all devices (Figure 3) with mean C_t increases being 14.9 from FlowFlex,
 13.3 from Surescreen, 11.4 from OrientGene and 12.5 from Innova.
 No clear correlation was seen between the C_t of the eluted material and the percentage of genome
- recovered for FlowFlex and Surescreen devices. For OrientGene and Innova devices a trend was
- observed of Ct below 30 being sufficient to provide >70% genome recovery consistently, with
- 166 higher C_t values providing more mixed results (Figure 4).
- 167



Figure 3. qRT-PCR Ct from original sample and in the corresponding material eluted from

- 170 **LFD.**
- 171



172

Figure 4. Comparison of percentage consensus genome sequence recovery from clinical
 samples compared to the viral titre of material eluted from the used LFDs. Red line indicates
 70% genome recovery.

- 176
- 177

178 **Process optimisation and evaluation of the centrifugation method using clinical samples**

Experiments initially followed the procedure for LFD strip extraction as set out by *Martin et al.*, 2022. This process is time consuming and labour intensive, therefore, we set out to test the process of elution of sample in extraction buffer directly from the LFD via centrifugation as described by Macori *et al.*, 2022.

183

For initial comparison the irradiated SARS-CoV-2 series, was processed in triplicate, across three time points, on each device by both methods. LFD centrifugation provided equivalent or improved genome coverage for all device brands (See Supplemental Table 1). A further comparison between the two extraction methods was made using residual clinical samples. The clinical

samples tested were not paired but comprised of two batches containing samples with a clinically representative C_t range. Results from elution by centrifugation remained comparable to those from the strip removal extraction method when using clinical samples (Figure 5). The percentage of samples with a positive lineage call, comparing strip removal to centrifugation was 21.7% to 29.4%, 21.7% to 17.7%, 78.2% to 76.4% and 78.2% to 76.4%, for FlowFlex, SureScreen, OrientGene and Innova devices respectively.

194



195

Figure 5. Distribution of percentage consensus genome sequence recovery following
 elution via strip removal (opened) or centrifugation (spun) method from clinical samples
 for all four LFD devices tested. Red line indicates 70% genome recovery.

200 Assessment of sample viability upon LFDs over seven days of ambient incubation.

201 Real-world use of LFDs as a sample source for sequencing applications raises logistical issues 202 that are likely to include delays between initial sample LFD testing and laboratory processing. particularly in home-use scenarios. We set out to assess the impact of delayed time of LFD 203 204 sample receipt and processing on the ability to recover informative genome sequences. An irradiated SARS-CoV-2 dilution series was used to assess the effect of such delays ranging up to 205 206 seven days in duration. Stability of the nucleic acid in the used LFD as measured by genome sequence recovery was assessed for each device, from dilution in LFD buffer without being run 207 208 on the device to running followed by multiple days incubation upon the device post-use, at room 209 temperature, prior to extraction (Figure 6).

210

211 Decreased genome recovery was seen with increased delay time for all devices. The highest titre

tested (equivalent C_t 18) provided sufficient genomic coverage for multiple days on FlowFlex,

213 OrientGene and Innova devices (Figure 4) but the signal rapidly degraded on Surescreen devices.

214 The Ct 25 equivalent sample showed inconsistent signal over multiple days on OrientGene and

215 Innova devices but was rapidly degraded on FlowFlex and SureScreen devices.



216

Figure 6. Percentage consensus genome sequence recovery following elution of a range of titres of SARS-COV-2 virions from the four LFD devices tested. Buffer indicates incubation in buffer without being run on a device. Red line indicates 70% genome recovery.

220

222 The effect of delayed time to elution on recovery from LFDs using residual clinical sample

223 material

Residual clinical samples were used to assess the effect of delayed time to elution on recovery from LFDs. Ten clinical samples were tested on each of 4 LFD brands over the course of 3 days. Decreased genome recovery is seen over time in all cases, but OrientGene and Innova devices still provided sufficient genome coverage for lineage calling from 60% and 50% of clinical samples tested after 2 days incubation. FlowFlex and SureScreen produced reduced genome coverage from the samples tested, even in the absence of delayed recovery (Table 1).

- 230
- 231

| | Percent of samples with Lineage Call | | | | | |
|------------|--------------------------------------|-------|-------|--|--|--|
| | Day 0 | Day 1 | Day 2 | | | |
| FlowFlex | 30 | 20 | 0 | | | |
| SureScreen | 30 | 20 | 0 | | | |
| OrientGene | 90 | 60 | 60 | | | |
| Innova | 80 | 70 | 50 | | | |

Table 1. Percentage of clinical samples from which sufficient genome sequence was
 recovered from each LFD brand following either immediate extraction for sequencing (Day
 0) or ambient incubation on the device (Day 1, Day 2).

235

236

The effect of nucleic acid preservatives on recovery from LFDs over five days of ambient incubation

Addition of three RNA stabilising agents to devices post running of a mid-titre SARS-COV-2 mock sample (10³ PFU.ml) show varied results. DNA/RNA shield and RNALater preserved RNA and allowed near complete genome sequencing after 5 days room temperature incubation on both OrientGene and Innova devices. Inhibisure was similarly effective on the Innova device but showed no preservative effect on OrientGene devices. Results on FlowFlex were inconsistent for all preservatives tested (Figure 7).



246



248 days of ambient incubation. Red line indicates 70% genome recovery.

249 Discussion

In this study we set out to assess the feasibility of SARS-CoV-2 amplicon sequencing using LFD eluates from four major LFD brands currently in use in the UK, with the aim of generating a protocol that could subsequently be expanded to other potential use settings, such as support for future variant monitoring programs. The LFDs used in this study were not designed to be compatible for use with downstream genomic studies, as such device performances are not a reflection of their ability to detect SARS-CoV-2 when used for their intended purpose.

256

257 Our evaluation using inactivated SARS-COV-2 observed recovery of sufficient sequence 258 information for lineage assignment at titres as low as 10³ PFU/mI (sample Ct ~25) from three of 259 the four evaluated major devices currently in use within the UK.

260

Our assessment of genome recovery from 40 residual clinical nasal swab samples (C_t range from 13 to 24) for each LFD type found reduced genome recovery for clinical samples from FlowFlex and SureScreen devices (25% and 20% of samples with a lineage call respectively) when compared to OrientGene and Innova devices (80% and 80% of samples with a lineage call respectively).

266

Rector *et al.*, 2022 tested a range of LFD brands, using stored nasopharyngeal samples, they found that LFD buffer components can be deleterious for the viral genetic material, resulting in lower RNA concentrations and interfering with sequencing. In our study, a similar reduction in viral concentration was seen in LFD eluates of all brands compared to the originating clinical samples. Indicating that reduced elution efficiency is unlikely to be the cause of poorer genome recovery via amplicon sequencing in some devices. Increased levels of fragmentation or the presence of inhibitors may be significant factors.

274

The process of removing strips from LFD casings for nucleic acid extraction is time consuming, labour intensive and not feasible for use in high throughput processing. Work by Macori *et al.,* 2022 described an extraction method by centrifugation. In our study, we confirmed LFD centrifugation provided equivalent or improved genome coverage for all device brands.

279

Decreased genome recovery was seen with increased delay time for all devices. OrientGene and
 Innova showed the best recovery over time, with 60/70% or samples showing sufficient stability
 after two days to retrieve near complete genome sequences. For all LFD brands considerable

loss of recovery from clinically representative titrations was seen from day three onwards.
 Interestingly, Martin *et al.*, 2022 found that SARS-CoV-2 genomes could be successfully
 recovered from Abbott and InnoScreen brand test devices up to 8 days after initial sample
 collection.

287

The addition of commercial nucleic-acid-stabilising reagents to devices after run completion showed promise. Both RNALater and DNA/RNA shield showed preservative effect over several days upon the typically best yielding devices, OrientGene and Innova, as has been observed by Moso *et al.*, 2024 for multiple RNA viruses on the PanBio COVID-19 device. Neither preservative however improved the recovery from the FlowFlex device.

293

LFDs are not designed to be compatible with extracting genetic material suitable for sequencing. However, building on the observations of *Martin et al.*, 2022 and others, we have verified that it is feasible to retrieve adequate genetic material for targeted amplicon sequencing from some of these devices. Our work extends this finding to various LFDs currently deployed in the UK, showing that genomic recovery varies across different devices. Accordingly, a comprehensive assessment of each LFD type is required to determine its suitability as a genomic sequencing sample source.

301

Consideration should be given as to whether future iterations of LFDs should incorporate the capability to efficiently sequence pathogens from the eluate as a design requirement or how this could otherwise be achieved efficiently and effectively.

305

306 We suggest the following next steps:

Conduct a comprehensive comparative study to quantify the efficiency of genomic
 recovery across different LFD brands and models working with representative
 suppliers. This study should aim to identify factors that influence the variability in
 recovery rates.

- 2. Engage with LFD manufacturers to share findings and collaborate on the
 development of next-generation devices that include the efficient recovery of genetic
 material as a key design objective.
- 3. Work towards establishing a set of guidelines or standards for evaluating LFD 3. work towards establishing a set of guidelines or standards for evaluating LFD 3. suitability as sources of genetic material for sequencing. These guidelines may help 3. streamline the assessment process for new or existing LFD types.

317 References

- Marjanovic S, Romanelli RJ, Ali GC, Leach B, Bonsu M, Rodriguez-Rincon D, Ling T.
 COVID-19 Genomics UK (COG-UK) Consortium: Final Report. Rand Health Q. 2022 Aug
 31;9(4):24. PMID: 36238008; PMCID: PMC9519096.
- COVID-19 Genomics UK (COG-UK) consortium. An integrated national scale SARS-CoV genomic surveillance network. Lancet Microbe. 2020 Jul;1(3):e99-e100. doi:
 10.1016/S2666-5247(20)30054-9. Epub 2020 Jun 2. PMID: 32835336; PMCID:
 PMC7266609.
- Eyre DW, Futschik M, Tunkel S, Wei J, Cole-Hamilton J, Saquib R, Germanacos N, Dodgson AR, Klapper PE, Sudhanva M, Kenny C, Marks P, Blandford E, Hopkins S, Peto TEA, Fowler T. Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study. Lancet Infect Dis. 2023 Aug;23(8):922-932. doi: 10.1016/S1473-3099(23)00129-9. Epub 2023 Mar 28. PMID: 37001541; PMCID: PMC10048397.
- Martin GE, Taiaroa G, Taouk ML, Savic I, O'Keefe J, Quach R, Prestedge J, Krysiak M,
 Caly L, Williamson DA. Maintaining genomic surveillance using whole-genome
 sequencing of SARS-CoV-2 from rapid antigen test devices. Lancet Infect Dis. 2022
 Oct;22(10):1417-1418. doi: 10.1016/S1473-3099(22)00512-6. Epub 2022 Aug 4. PMID:
 35934015; PMCID: PMC9352270.
- Moso MA, Taiaroa G, Steinig E, Zhanduisenov M, Butel-Simoes G, Savic I, Taouk ML, Chea S, Moselen J, O'Keefe J, Prestedge J, Pollock GL, Khan M, Soloczynskyj K, Fernando J, Martin GE, Caly L, Barr IG, Tran T, Druce J, Lim CK, Williamson DA. Non-SARS-CoV-2 respiratory viral detection and whole genome sequencing from COVID-19 rapid antigen test devices: a laboratory evaluation study. Lancet Microbe. 2024 Apr;5(4):e317-e325. doi: 10.1016/S2666-5247(23)00375-0. Epub 2024 Feb 12. PMID: 38359857.
- Rector A, Bloemen M, Schiettekatte G, Maes P, Van Ranst M, Wollants E. Sequencing directly from antigen-detection rapid diagnostic tests in Belgium, 2022: a gamechanger in genomic surveillance? Euro Surveill. 2023 Mar;28(9):2200618. doi: 10.2807/1560-7917.ES.2023.28.9.2200618. PMID: 36862099; PMCID: PMC9983067.
- Macori G, Russell T, Barry G, McCarthy SC, Koolman L, Wall P, Sammin D, Mulcahy G,
 Fanning S. Inactivation and Recovery of High Quality RNA From Positive SARS-CoV-2
 Rapid Antigen Tests Suitable for Whole Virus Genome Sequencing. Front Public Health.

350 2022 May 3;10:863862. doi: 10.3389/fpubh.2022.863862. PMID: 35592078; PMCID: 351 PMC9113430. 352 8. Josh Quick, Lauren Lansdowne 2024. ARTIC SARS-CoV-2 seguencing protocol v4 (LSK114). protocols.io https://dx.doi.org/10.17504/protocols.io.bp2l6n26rgge/v4 353 354 9. https://community.artic.network/t/sars-cov-2-version-5-3-2-scheme-release/462 10. https://github.com/artic-network/artic-ncov2019 355 11. Áine O'Toole, Emily Scher, Anthony Underwood, Ben Jackson, Verity Hill, John T 356 McCrone, Rachel Colquhoun, Chris Ruis, Khalil Abu-Dahab, Ben Taylor, Corin Yeats, 357 Louis Du Plessis, Daniel Maloney, Nathan Medd, Stephen W Attwood, David M Aanensen, 358 Edward C Holmes, Oliver G Pybus, Andrew Rambaut (2021) Virus Evolution 359 DOI:10.1093/ve/veab064 360 361 362 363 364 365 366

367 Supplemental

| F | ow | F | lex |
|---|------|---|-----|
| | 0 00 | | |

| Viral Titre | Day 0 | | Day 1 | | Day 2 | |
|-------------|-------------------|-------|--------|-------|--------|-------|
| PFU/ML | Opened | Spun | Opened | Spun | Opened | Spun |
| 10^5 | 97.7 | 98.48 | 94.91 | 97.59 | 78.04 | 83.6 |
| 10^3 | 78.85 | 93.21 | 31.46 | 84.53 | 11.22 | 36.94 |
| 10^2 | 23.31 | 58.32 | 3.57 | 39.25 | 3.46 | 28.4 |
| 10^1 | 4.51 | 17.75 | 1.11 | 3.23 | 0 | 1.18 |
| 10^0 | 0 | 4.55 | 0 | 0 | 0 | 0 |
| SureScreen | | | | | | |
| Viral Titre | Viral Titre Day 0 | | Day | 1 | Day 2 | 2 |
| PFU/ML | Opened | Spun | Opened | Spun | Opened | Spun |
| 10^5 | 62.62 | 70.04 | 0 | 7.68 | 21.64 | 26.44 |
| 10^3 | 1.16 | 19.78 | 0 | 1.19 | 8.13 | 6.79 |
| 10^2 | 1.19 | 4.51 | 0 | 0 | 23.57 | 0 |
| 10^1 | 0 | 4.48 | 0 | 0 | 0.85 | 0 |
| 10^0 | 0 | 0 | 0 | 0 | 0 | 0 |
| OrientGene | | | | | | |
| Viral Titre | Day | 0 | Day | 1 | Day 2 | 2 |
| PFU/ML | Opened | Spun | Opened | Spun | Opened | Spun |
| 10^5 | 97.7 | 99.45 | 99.44 | 98.5 | 97.67 | 98.51 |
| 10^3 | 74.38 | 98.49 | 89.33 | 93.13 | 45.31 | 88.67 |
| 10^2 | 33.41 | 86.53 | 40.83 | 53.68 | 12.5 | 37.63 |
| 10^1 | 5.08 | 72.18 | 11.39 | 0 | 2.05 | 9.06 |
| 10^0 | 1.15 | 38.31 | 0 | 1.19 | 1.09 | 4.59 |
| Innova | | | | | | |
| Viral Titre | Viral Titre Day 0 | | Day 1 | | Day 2 | |
| PFU/ML | Opened | Spun | Opened | Spun | Opened | Spun |
| 10^5 | 97.69 | 99.43 | 98.52 | 99.43 | 97.7 | 92.43 |
| 10^3 | 73.91 | 97.58 | 79.04 | 97.28 | 64.61 | 82.06 |
| 10^2 | 59.2 | 94.39 | 39.97 | 86.7 | 18.37 | 49.65 |
| 10^1 | 8.11 | 75.53 | 7.92 | 29.53 | 0 | 1.09 |
| 10^0 | 0 | 30.95 | 0.98 | 2.25 | 0 | 0 |

368

369 Supplementary Table 1. Comparison of percentage consensus genome sequence recovery

370 following elution via strip removal (opened) or centrifugation (spun) method of a range of

371 titres of SARS-COV-2 virions of all four LFD devices tested. Colour coded from green (high)

372 to red (low) coverage.